A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Investor's Business Daily on MSN3d
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Set To Break OutBristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock jumped, signaling a breakout.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
Here are the top performances in football from last week. Please email your top performers each week to ...
Patton Kizzire ended a long victory drought Sunday in the Procore Championship, closing with a scrambling 2-under 70 for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback